Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures sink as AI doubts resurface, oil jumps
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| (NASDAQ: ANAB) | Delayed: 47.94 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.94 | 52 Week High | $ | |||
| Open | $47.94 | 52 Week Low | $ | |||
| Day High | $47.94 | P/E | N/A | |||
| Day Low | $47.94 | EPS | $ | |||
| Volume | 7,756 | |||||
